Literature DB >> 28389175

Validation of a multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus.

Thierry Dervieux1, John Conklin2, Jo-Anne Ligayon2, Leilani Wolover2, Tyler O'Malley2, Roberta Vezza Alexander2, Arthur Weinstein3, Claudia A Ibarra2.   

Abstract

BACKGROUND: We describe the analytical validation of an assay panel intended to assist clinicians with the diagnosis of systemic lupus erythematosus (SLE). The multi-analyte panel includes quantitative assessment of complement activation and measurement of autoantibodies.
METHODS: The levels of the complement split product C4d bound to erythrocytes (EC4d) and B-lymphocytes (BC4d) (expressed as mean fluorescence intensity [MFI]) are measured by quantitative flow cytometry, while autoantibodies (inclusive of antinuclear and anti-double stranded DNA antibodies) are determined by immunoassays. Results of the multi-analyte panel are reported as positive or negative based on a 2-tiered index score. Post-phlebotomy stability of EC4d and BC4d in EDTA-anticoagulated blood is determined using specimens collected from patients with SLE and normal donors. Three-level C4 coated positive beads are run daily as controls. Analytical validity is reported using intra-day and inter-day coefficient of variation (CV).
RESULTS: EC4d and BC4d are stable for 2days at ambient temperature and for 4days at 4°C post-phlebotomy. Median intra-day and inter-day CV range from 2.9% to 7.8% (n=30) and 7.3% to 12.4% (n=66), respectively. The 2-tiered index score is reproducible over 4 consecutive daysupon storage of blood at 4°C. A total of 2,888 three-level quality control data were collected from 6 flow cytometers with an overall failure rate below 3%. Median EC4d level is 6 net MFI (Interquartile [IQ] range 4-9 net MFI) and median BC4d is 18 net MFI (IQ range 13-27 net MFI) among 86,852 specimens submitted for testing. The incidence of 2-tiered positive test results is 13.4%.
CONCLUSION: We have established the analytical validity of a multi-analyte assay panel for SLE.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarkers; Complement; Diagnostic immunology

Mesh:

Substances:

Year:  2017        PMID: 28389175     DOI: 10.1016/j.jim.2017.04.001

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

1.  Increased Levels of Circulating Glial Fibrillary Acidic Protein and Collapsin Response Mediator Protein-2 Autoantibodies in the Acute Stage of Spinal Cord Injury Predict the Subsequent Development of Neuropathic Pain.

Authors:  Georgene W Hergenroeder; John B Redell; H Alex Choi; Lisa Schmitt; William Donovan; Gerard E Francisco; Karl Schmitt; Anthony N Moore; Pramod K Dash
Journal:  J Neurotrauma       Date:  2018-07-05       Impact factor: 5.269

2.  Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE.

Authors:  Michelle A Petri; John Conklin; Tyler O'Malley; Thierry Dervieux
Journal:  Lupus Sci Med       Date:  2019-03-30

3.  Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome.

Authors:  Paola Adele Lonati; Mariangela Scavone; Maria Gerosa; Maria Orietta Borghi; Francesca Pregnolato; Daniele Curreli; Gianmarco Podda; Eti Alessandra Femia; Wilma Barcellini; Marco Cattaneo; Francesco Tedesco; Pier Luigi Meroni
Journal:  Front Immunol       Date:  2019-04-12       Impact factor: 7.561

4.  Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE.

Authors:  Daniel J Wallace; Roberta Vezza Alexander; Tyler O'Malley; Arezou Khosroshahi; Mehrnaz Hojjati; Konstantinos Loupasakis; Jeffrey Alper; Yvonne Sherrer; Maria Fondal; Rajesh Kataria; Tami Powell; Claudia Ibarra; Sonali Narain; Elena Massarotti; Arthur Weinstein; Thierry Dervieux
Journal:  Lupus Sci Med       Date:  2019-09-19

5.  Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus.

Authors:  Rosalind Ramsey-Goldman; Roberta Vezza Alexander; Elena M Massarotti; Daniel J Wallace; Sonali Narain; Cristina Arriens; Christopher E Collins; Amit Saxena; Chaim Putterman; Kenneth C Kalunian; Tyler O'Malley; Thierry Dervieux; Arthur Weinstein
Journal:  Arthritis Rheumatol       Date:  2019-11-25       Impact factor: 10.995

Review 6.  Cell-bound complement activation products in SLE.

Authors:  Rosalind Ramsey-Goldman; Jian Li; Thierry Dervieux; Roberta Vezza Alexander
Journal:  Lupus Sci Med       Date:  2017-08-21

7.  Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.

Authors:  Joan T Merrill; Michelle A Petri; Jill Buyon; Rosalind Ramsey-Goldman; Kenneth Kalunian; Chaim Putterman; John Conklin; Richard A Furie; Thierry Dervieux
Journal:  Lupus Sci Med       Date:  2018-05-23

8.  Cell-bound complement activation products associate with lupus severity in SLE.

Authors:  Cristina Arriens; Roberta Vezza Alexander; Sonali Narain; Amit Saxena; Christopher E Collins; Daniel J Wallace; Elena Massarotti; John Conklin; Kenneth C Kalunian; Chaim Putterman; Rosalind Ramsey-Goldman; Jill P Buyon; Anca Askanase; Richard A Furie; Judith A James; Ghalib A Bello; Susan Manzi; Joseph Ahearn; Tyler O'Malley; Arthur Weinstein; Thierry Dervieux
Journal:  Lupus Sci Med       Date:  2020-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.